Replimune Group Inc（REPL）股票分析REPLReplimune Group Inc

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Replimune Group Inc is currently a hold. The stock is priced at $11.46, which is below the analyst price targets of $20 and $21, suggesting potential upside. However, the RSI is at 40.403, indicating a lack of strong momentum, and the company has reported significant net losses, with a net income of -66.34 million in Q3 2025 and a forward P/E of 0, reflecting ongoing financial challenges. The main risk is the high debt-to-equity ratio, which has increased to 102.89% in Q1 2027, indicating potential financial instability.

3 analysts cover REPL: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.43.